Literature DB >> 22374657

[Malignant pleural mesothelioma].

T Ploenes1, T Osei-Agyemang, U Nestle, C F Waller, B Passlick.   

Abstract

Malignant pleural mesothelioma (MMP) is a highly aggressive tumor arising of the pleural mesothelium. Asbestos exposure is the main factor involved in the pathogenesis of MMP and according to the late ban of this agent in 2005 the peak incidence in Europe is expected in the next twenty years. The highly aggressive behaviour of this tumor results in a poor prognosis with a mean overall survival between 7 and 9 months. Despite the progress made in diagnosis and therapy of this entity the optimal treatment remains a subject of debate. In this article we review the current state of treatment and diagnosis. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22374657     DOI: 10.1055/s-0031-1298905

Source DB:  PubMed          Journal:  Dtsch Med Wochenschr        ISSN: 0012-0472            Impact factor:   0.628


  3 in total

1.  [Regional treatment of malignant pleural mesothelioma: results from the tumor centre Regensburg].

Authors:  M Ried; U Speth; T Potzger; R Neu; C Diez; M Klinkhammer-Schalke; H-S Hofmann
Journal:  Chirurg       Date:  2013-11       Impact factor: 0.955

2.  Turning back the Wheel: Inducing Mesenchymal to Epithelial Transition via Wilms Tumor 1 Knockdown in Human Mesothelioma Cell Lines to Influence Proliferation, Invasiveness, and Chemotaxis.

Authors:  Till Plönes; Mitja Fischer; Kerstin Höhne; Hiromi Sato; Joachim Müller-Quernheim; Gernot Zissel
Journal:  Pathol Oncol Res       Date:  2017-01-04       Impact factor: 3.201

3.  Absence of amplification of the FGFR1-gene in human malignant mesothelioma of the pleura: a pilot study.

Authors:  Till Plönes; Frank Beckers; Walburga Engel-Riedel; Erich Stoelben; Michael Brockmann; Verena Schildgen; Oliver Schildgen
Journal:  BMC Res Notes       Date:  2014-08-19
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.